Table 4.
ED Visits for ADEs |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient Age ≤5 yb |
Patient Age 6-19 yb |
Patient Age 20-34 y |
Patient Age 35-49 y |
Patient Age 50-64 y |
Patient Age 65-79 y |
Patient Age ≥80 y |
||||||||
Drug Class | No. of Cases (n = 2741) |
National Estimate, % (95% CI)c |
No. of Cases (n = 3240) |
National Estimate, % (95% CI)c |
No. of Cases (n = 5638) |
National Estimate, % (95% CI)c |
No. of Cases (n = 5928) |
National Estimate, % (95% CI)c |
No. of Cases (n = 8797) |
National Estimate, % (95% CI)c |
No. of Cases (n = 8266) |
National Estimate, % (95% CI)c |
No. of Cases (n = 5370) |
National Estimate, % (95% CI)c |
Antibiotics | 1460 | 56.4 (51.8-61.0) |
870 | 31.8 (28.7-34.9) |
1257 | 24.2 (21.5-26.9) |
873 | 16.2 (14.1-18.2) |
832 | 11.1 (9.8-12.4) |
447 | 6.3 (5.3-7.3) |
242 | 5.8 (4.5-7.0) |
Anticoagulants | 6 | NA | 13 | NA | 133 | 2.1 (1.6-2.6) |
454 | 7.2 (5.2-9.2) |
1240 | 13.7 (11.1-16.4) |
2233 | 27.5 (23.3-31.7) |
2206 | 38.8 (33.7-43.8) |
Antidepressants | 6 | NA | 107 | 3.8 (2.5-5.1) |
184 | 3.5 (2.6-4.3) |
157 | 2.7 (2.0-3.5) |
126 | 1.7 (1.2-2.1) |
55 | 0.8 (0.6-1.0) |
24 | 0.7 (0.1-1.3)d |
Antineoplastic agents | 283 | 2.8 (0-6.0)d |
330 | 2.7 (0-5.8)d |
106 | 1.3 (0.5-2.1)d |
196 | 2.3 (1.1-3.6) |
546 | 5.2 (3.1-7.4) |
384 | 3.6 (2.0-5.2) |
92 | 1.4 (0.7-2.1) |
Antiplatelets | 1 | NA | 16 | NA | 37 | 0.5 (0.3-0.7) |
68 | 1.3 (0.7-1.9) |
359 | 4.3 (3.1-5.5) |
657 | 8.0 (5.7-10.4) |
615 | 10.6 (8.3-12.9) |
Antipsychotics | 7 | NA | 137 | 4.5 (3.3-5.6) |
340 | 5.2 (3.9-6.5) |
228 | 3.1 (2.2-4.0) |
176 | 1.9 (1.4-2.4) |
41 | 0.5 (0.3-0.6) |
13 | NA |
Diabetes agents | 10 | NA | 100 | 2.8 (1.8-3.8) |
499 | 7.3 (5.3-9.2) |
891 | 14.2 (11.3-17.2) |
1786 | 18.2 (14.8-21.7) |
1722 | 18.6 (14.9-22.4) |
839 | 15.2 (11.4-19.0) |
Dietary supplementse | 46 | 1.8 (0.8-2.8) |
55 | 2.0 (1.3-2.6) |
201 | 3.7 (3.0-4.4) |
174 | 2.9 (2.5-3.4) |
125 | 1.4 (1.0-1.7) |
72 | 1.0 (0.7-1.3) |
38 | 1.0 (0.6-1.3) |
Non-opioid-containing analgesics | 36 | 1.6 (0.9-2.4) |
49 | 1.7 (0.9-2.5) |
88 | 1.6 (1.1-2.0) |
68 | 1.1 (0.7-1.5) |
31 | 0.3 (0.1-0.5)d |
11 | NA | 5 | NA |
Nonsteroidal anti-inflammatory drugs | 52 | 2.8 (1.7-3.9) |
117 | 3.9 (2.8-5.0) |
225 | 4.0 (3.2-4.8) |
166 | 3.2 (2.6-3.7) |
132 | 1.5 (1.2-1.8) |
69 | 0.8 (0.5-1.0) |
18 | NA |
Opioid analgesics | 20 | 0.6 (0.1-1.0)d |
93 | 3.0 (2.2-3.8) |
422 | 7.8 (6.8-8.8) |
382 | 6.8 (5.7-7.9) |
536 | 6.9 (5.9-8.0) |
354 | 4.6 (3.9-5.4) |
151 | 3.5 (2.6-4.5) |
Sedative or hypnotic agents | 11 | NA | 55 | 2.0 (1.1-2.9) |
128 | 2.3 (1.4-3.1) |
160 | 2.8 (1.8-3.7) |
145 | 1.6 (1.2-2.1) |
106 | 1.4 (0.9-1.9) |
53 | 0.9 (0.5-1.3) |
Stimulants | 13 | NA | 116 | 3.8 (2.8-4.7) |
50 | 0.9 (0.5-1.3) |
18 | NA | 5 | NA | 4 | NA | 1 | NA |
Vaccines | 455 | 19.5 (16.2-22.8) |
111 | 3.7 (2.8-4.6) |
89 | 1.8 (1.3-2.4) |
89 | 1.6 (1.0-2.1) |
81 | 1.1 (0.8-1.3) |
64 | 0.8 (0.5-1.1) |
16 | NA |
All other drug classesf | 284 | 10.5 (8.2-12.7) |
860 | 26.8 (24.6-29.1) |
1454 | 26.3 (24.3-28.3) |
1522 | 26.3 (24.6-28.0) |
1986 | 23.2 (21.0-25.4) |
1328 | 16.9 (14.5-19.3) |
548 | 11.6 (9.0-14.1) |
>1 Drug class implicated | 51 | 1.7 (0.9-2.5) |
211 | 6.9 (5.7-8.1) |
425 | 7.5 (6.3-8.8) |
482 | 7.9 (7.0-8.8) |
691 | 7.8 (6.6-8.9) |
719 | 8.8 (7.1-10.6) |
509 | 9.5 (6.8-12.2) |
Abbreviation: NA, estimates based on fewer than 20 cases are considered statistically unreliable and are not shown.
Data are based on 42 585 cases from the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance project, US Centers for Disease Control and Prevention. Data exclude ED visits for abuse or self-harm. Data for specific drug classes represent only ED visits in which a single drug class was implicated. Patient age missing for 1 case.
Excludes ED visits for unsupervised medication ingestions by children aged 10 years or younger.
Calculated from statistical weighting of cases based on the sample design.
Coefficient of variation greater than 30%.
In addition to related products.
In which a single drug class was implicated.